Wegovy (Semaglutide 2.4 mg) Diarrhea Severity Grading Rubric

What the Wegovy Label Reports

The label pools three randomized, double-blind, placebo-controlled trials: 2,116 adults on 2.4 mg weekly and 1,261 on placebo, treated for up to 68 weeks [1]. Diarrhea was reported by 30% versus 16%, second only to nausea at 44% versus 16%, and any gastrointestinal reaction by 73% versus 47% [1].

How Often People Stopped Wegovy Because of Diarrhea

Diarrhea led to stopping treatment in 0.7% of adults taking Wegovy 2.4 mg versus 0.1% taking placebo [1]. That puts it behind nausea (1.8% versus 0.2%) and vomiting (1.2% versus 0%) as a reason for discontinuation, within an overall discontinuation rate for adverse reactions of 6.8% versus 3.2% [1].

In STEP 1, the 68-week trial of 1,961 adults without diabetes, gastrointestinal events led to discontinuation in 4.5% of semaglutide participants versus 0.8% on placebo [2].

The label separately reports severe gastrointestinal reactions of any kind in 4.1% of injection-treated adults versus 0.9% taking placebo [1]. Its gastrointestinal warning says use is associated with gastrointestinal adverse reactions, sometimes severe, and that Wegovy is not recommended in patients with severe gastroparesis [1]. Postmarketing reports include ileus and intestinal obstruction, and the label says frequency cannot be estimated from voluntary reports [1].

Dehydration and Kidney Risk

The label's concern about fluid loss is the kidney. It warns about acute kidney injury due to volume depletion and says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1]. In the Wegovy trials, acute kidney injury occurred at 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in patients with prior renal impairment and during dose titration, and often after gastrointestinal fluid loss [1].

Do Dose Steps, Age or Diabetes Change the Picture?

The injection is titrated every 4 weeks: 0.25 mg in weeks 1 to 4, 0.5 mg in weeks 5 to 8, 1 mg in weeks 9 to 12, 1.7 mg in weeks 13 to 16, then maintenance from week 17 at 2.4 mg (recommended) or 1.7 mg [1]. An earlier version of the Wegovy injection label (April 2024) says that if patients do not tolerate a dose during escalation, consider delaying escalation for 4 weeks [3].

Rates differ by group. Diarrhea was reported by 22% of adolescents aged 12 and older on 2.4 mg versus 19% on placebo [1]. In adults with type 2 diabetes in STEP 2 (1,210 participants), gastrointestinal adverse events of any kind occurred in 63.5% on 2.4 mg versus 34.3% on placebo [4].

Loperamide and Oral Antidiarrheals

Loperamide is an over-the-counter antidiarrheal that reduces peristalsis and fluid secretion and lengthens gut transit time [5]. The Wegovy label's drug interactions section addresses insulin and insulin secretagogues, where the concern is hypoglycemia, and says that Wegovy delays gastric emptying and may affect absorption of oral medicines [1]. We found no study that tested loperamide with semaglutide.